Patents by Inventor Alexandra CROFT
Alexandra CROFT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952408Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: September 28, 2018Date of Patent: April 9, 2024Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
-
Publication number: 20230256018Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: ApplicationFiled: June 30, 2022Publication date: August 17, 2023Applicant: Juno Therapeutics, Inc.Inventors: Stephen Jacob GOLDFLESS, Brian BELMONT, Cameron BRANDT, Alexandra CROFT, David Jeffrey HUSS
-
Patent number: 11471489Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: GrantFiled: April 3, 2019Date of Patent: October 18, 2022Assignee: Juno Therapeutics, Inc.Inventors: Stephen Jacob Goldfless, Brian Belmont, Cameron Brandt, Alexandra Croft, David Jeffrey Huss
-
Publication number: 20210363258Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV16 E6 and HPV16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: July 23, 2021Publication date: November 25, 2021Applicant: Juno Therapeutics, Inc.Inventors: James SISSONS, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Publication number: 20210284709Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: September 28, 2018Publication date: September 16, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron BRANDT, Brian BELMONT, Christopher BORGES, Stephen Michael BURLEIGH, Alexandra CROFT, Stephen Jacob GOLDFLESS, David Jeffrey HUSS, Yue JIANG, Timothy G. JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Christopher Heath NYE, Haley PEPER, Blythe D. SATHER, Sonia TIMBERLAKE, Dean Y. TOY, Queenie VONG, Gordon Grant WELSTEAD, James SISSONS
-
Patent number: 11072660Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: October 3, 2017Date of Patent: July 27, 2021Assignee: Juno Therapeutics, Inc.Inventors: James Sissons, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Publication number: 20190321401Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: ApplicationFiled: April 3, 2019Publication date: October 24, 2019Applicant: Juno Therapeutics, Inc.Inventors: Stephen Jacob GOLDFLESS, Brian BELMONT, Cameron BRANDT, Alexandra CROFT, David Jeffrey HUSS
-
Publication number: 20190225692Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: October 3, 2017Publication date: July 25, 2019Applicant: Juno Therapeutics, Inc.Inventors: James SISSONS, Cameron BRANDT, Alexandra CROFT, Allen EBENS, Haley PEPER, Dean Y. TOY, Brian BELMONT, Stephen GOLDFLESS, Yue JIANG, Timothy JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Blythe SATHER, Sonia TIMBERLAKE